pharmaceuticals PM market analysis — 2026-08-28

Eli Lilly has secured an FDA label expansion for Mounjaro to cover cardiovascular-risk reduction in certain adults with type 2 diabetes, sharpening its rivalry with Novo Nordisk on clinical grounds rather than price alone. The move gives Lilly a broader prescribing case with physicians and payers weighing treatment choices against established cardiovascular-outcomes data.

Separately, the arrival of oral GLP-1 therapies is reshaping the obesity-drug market into a contest over convenience, coverage and brand recognition, alongside the underlying clinical profile. How quickly prescribers and insurers adapt to pill-based options against injectable incumbents will shape uptake more than efficacy claims in isolation.

At the portfolio level, Teva’s pursuit of BioXcel’s neuroscience assets through bankruptcy proceedings points to ongoing consolidation, with larger manufacturers continuing to acquire distressed but strategically relevant drug portfolios. Taken together, the week’s developments show competitive dynamics in pharma being driven by regulatory expansion, access and consolidation rather than a single dominant catalyst.